Anti-Syndecan 2 Antibody Treatment Reduces Edema Formation and Inflammation of Murine Laser-Induced CNV
Intravitreal anti-Sdc2 treatment may avoid side effects observed with the long-term anti-VEGF therapy, and systemic treatment with an anti-Sdc2 pAb antibody can address the issues associated with repeated intravitreal injections.
Authors
- Federico Corti (ORCID: https://orcid.org/0000-0003-2160-245X)
- Paola Perrotta (ORCID: https://orcid.org/0000-0002-3551-5560)
- Flavia Plastino (ORCID: https://orcid.org/0000-0001-8160-3273)
- Michael Simons (ORCID: https://orcid.org/0000-0003-0348-7734)
- Emma Ristori (ORCID: https://orcid.org/0000-0001-9999-2780)
- Helder André (ORCID: https://orcid.org/0000-0002-2926-2376)
- Filippo Locri (ORCID: https://orcid.org/0009-0000-3772-8730)
- Eric Song (ORCID: https://orcid.org/0000-0001-5448-5865)
- Xiangyun Yin (ORCID: https://orcid.org/0000-0003-0903-2319)
- Krisztina M. Zsebo
Institutions
- Karolinska Institutet (SE)
- Yale University (US)
- S:t Eriks Ögonsjukhus (SE)
Publication Details
- Journal
- Translational Vision Science & Technology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1167/tvst.14.1.10
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71
Funders
- Open Philanthropy Project
- National Institutes of Health